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INTRODUCTION
Endocrine disorders do occur among children in
developing countries, despite the high prevalence of
infectious diseases and malnutrition. Reports of
endocrine disorders in children in developing countries
are few compared to developed countries reflecting
the different level of prevalence in the different
geographical locations and or level of awareness and
availability of  facilities for proper diagnosis.
Multiple Pituitary Hormone Deficiency (MPHD) is an
endocrine disorder that causes short stature. It may
occur as a result of acquired lesions in the
hypothalamo-pituitary area such as tumour, surgery,
trauma, or irradiation. They may also be idiopathic or
result from genetically defined conditions. Congenital
MPHD may be familial in 10% of cases, but they are
usually sporadic1.
MPHD is characterized by impaired production of
GH and one or more of  the other pituitary hormones.
Some developmental genes that play critical role in
cell proliferation, cell differentiation and organ
commitment such as Hesx1, Lhx3, Lhx4, Prop1, PIT-
1, SOx3 and Sox2 have been implicated in MPHD2.
These genetic mutations and their inheritance were first
shown in mice and then in humans. They present with
variable phenotypes2.
The PIT-1 gene, the first pituitary-specific transcription
factor to be identified in the mouse and human,
encodes the POU-domain transcription factor PIT-1
which plays a major role in the normal development
of the anterior pituitary gland3-4. It is a 291-amino-
acid protein that is essential for the expression of the
PRL, GH and TSH genes3-4. PIT-1 is also required for
both specification and proliferation of somatotrophs,
lactotrophs and thyrotrophs to a limited extent4.
Therefore, PIT-1 mutations are associated with GH,
PRL and TSH deficiencies with TSH being highly
variable2.
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Background: In most developing countries, childhood endocrine
disorders are not as common as infections but they do occur. Multiple
pituitary hormone deficiency (MPHD) is a known cause of  familial
short stature. This is very rarely diagnosed in Nigerian children.
We describe the challenges of  diagnosis and management of
childhood endocrine conditions in a developing economy using a
ten year old Nigerian girl with MPHD as an illustration.
Methods: Patient had auxological data suggestive of short stature.
In order to make a definitive diagnosis, pituitary function tests were
carried out in the United Kingdom.
Results: Biochemical tests revealed growth hormone (GH)
deficiency, Thyroid Stimulating Hormone (TSH) deficiency,
decreased prolactin (PRL) level, normal cortisol and gonadotrophins.
Her DNA analysis identified PIT-1 mutation in exon-6. She was
placed on recombinant GH and thyroxine with evidence of catch
up in height.
Conclusions: There were challenges to management such as,
inadequate facility for diagnosis, huge cost of treatment and little
awareness about childhood endocrine conditions amongst health
workers in a developing economy.
Keywords: Multiple pituitary hormone deficiency (MPHD), PIT-1 mutation, short stature, management, developing country.
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There is very limited data on this condition in Nigerian
children. We use this case to illustrate the challenges of
diagnosis, management and of follow up of this
treatable endocrine condition in a developing country
and the implications for children with childhood
endocrine conditions in general.
Patient
Informed consent was obtained from the child and
her parents. This 10 year old girl was first referred at
the age of 2 years on account of poor growth from
birth.  She was born at term by spontaneous vaginal
delivery, after an uneventful pregnancy.  Her birth
weight was 2.8kg but her birth length was not
recorded. Neonatal period was normal.






(kg) BMI HeightSDS WeightSDS BMISDS
2.89 72 8 15.4 -6.08 -5.38 -0.40
5.23 82.6 11.6 17.3 -6.10 -4.16 1.10
7.34 95 18 19.9 -5.39 -2.06 1.80
Table 1:Growth Pattern over 4 years
Parents became worried about her growth from the
time she was 2 months of age. She was said to be
feeding well. Stool and bowel motions were normal.
No episodes of  recurrent diarrhoea and/or vomiting.
She had no history of chronic cough or breathlessness
and she had completed all childhood immunizations.
Her developmental milestones were within normal
limits.
She is the third of three children. Older siblings are of
normal height and weight. There is a positive history
of  short stature in her paternal grandfather.  Father’s
height is 178cm and mother’s height is 153cm. She has
a mid parental height around the 25th centile.
F ig u re  1 : S u b je c t’ s  G r o w t h  C h a r t  s h o w in g  h e i g h t v e lo c i ty  f r o m  2 – 7  y e a r s  o f  a g e
At presentation, she was small for age. She weighed
8kg with a height of 72cm, which was <0.4th centile
for age. Investigations such as chest radiograph,
electrocardiography, full blood count, urine culture and
urinalysis were all normal. Her haemoglobin
electrophoresis is A. Random blood sugar was 49mg/
dl, within normal limits. Electrolytes and urea were
normal.
At 5 years, her weight was 11.6kg (-4.2 standard
deviation score [SDS]) her height was 82.5cm (-6.1
SDS). She had subtle features of  GH deficiency. She
had a prominent forehead with flat nasal bridge and a
rather high palate. She has almond shaped eyes. Her
hands and feet were rather cool. Her cardiovascular
system was otherwise normal. Her nails were normal
but she had short fourth and fifth metacarpals. She
had a very prominent fatty abdomen with fatty breasts
and a marked lumbar lordosis.  Other systems were
normal.
She remained markedly short, 95 cm (-5.4 SDS) and
had become overweight at 7 years with body mass
index (BMI) SDS of  1.8.  Table 1 shows her growth
pattern over four years. Parents reported that she had
developed some psychosocial problems. She had
become very conscious of her extreme short stature,
she was shy and sometimes manipulative. Figure 1
shows her growth chart with growth velocity from
the age of  2.9 years to 7.3 years.
A diagnosis of marked short stature was made but
the cause was not defined. The following differential
diagnoses were considered, skeletal dysplasia, storage
disorder (mucopolysaccharidosis) and GH deficiency.
Further investigations were required for which facilities
were not available in Nigeria. He was subsequently
referred to and reviewed at the Royal Manchester
Children Hospital, Manchester, United Kingdom in
order to make a definitive diagnosis of the cause of
her short stature.
RESULTS
Table 2 is a summary of  the anterior pituitary function
tests carried out at Royal Manchester Children Hospital,
Manchester, United Kingdom.  The results revealed
Table 2: Su mm ary of P ituitary  In ve st ig at ions  in the U nited Kin gdo m
Te st Result Co mm ent
Arg inine Stim ulation  tes t - peak G H level <0.05m cg/l lo w
IG F-1 33ng/m l lo w
Prolact in <50m u/l lo w
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LH (U /l)      FSH (U /l)
<0.1              1.1
1.7                 10
2.6                 14 N or mal result
TR H  te st
Basal T SH
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peak GH < 0.05mcg/l with arginine stimulation test,
IGF-I was 33ng/ml (low) and prolactin was <50mU/
l (low). TRH test revealed low free T4 of 9 pmol/l,
normal basal TSH of  3.4mU/l and 3.3mU/l at 60
minutes.  There was normal cortisol and
gonadotrophins.
These results indicated severe GH deficiency, low
thyroxine with a normal basal TSH and a pituitary
response to Thyrotropin-releasing hormone (TRH),
undetectable prolactin, but normal cortisol response
to synacthen and gonadotrophins responses to
Gonadotropin-releasing hormone (GnRH).  These
results are consistent with PIT-1 deficiency. A DNA
sample was sent to screen for PIT-1 gene mutations
by DNA sequencing.
Figure 2 shows the result of the DNA analysis for
PIT-I Mutation.  There was heterozygous c>t change
(cgg>tgg, R>W). The dominant mutation was in PIT-
1 showing R271W mutation in exon 6.
The patient was subsequently commenced on thyroxine
75mcg daily and GH at 0.031mg/kg daily. Table 3
shows her growth pattern over 13 months of GH
therapy. Her height had increased by about 12cm. At
the age of 10 years, her height was 117cm, which is (-
3.2SDS).  Figure 3 illustrates the catch up in height
evidenced by crossing of centiles on the growth chart.
In addition to catch up in height, parents also reported
Figure 2: Result of DNA Analysis for PIT-I Mutation
• Heterozygous c>t change indicated by arrow
• (cgg>tgg, R>W)
• Dominant mutation in PIT-1
that there was improvement in the psychosocial
problems associated with short stature in this child.
DISCUSSION
In Nigeria, despite the high burden of childhood
infections, endocrine diseases are not uncommon. The
Coventry Consensus in 1998 recommended a single
height measurement of all children at school entry or
around the age of 5 years and prompt referral of
children with height less than 0.4th centile for further
assessment, in order to identify undetected and
treatable asymptomatic growth disorders.5 This is not
carried out routinely as recommended in Nigeria as in
many other African countries. Therefore, many cases
of short stature are undiagnosed and there is very little
data on short stature in Nigerian children. In 1992,
Famuyiwa reported 24 cases of short stature in Ibadan,
Nigeria. This was a descriptive study as no hormonal
data was available in most of the patients and in 4 of
them, the cause of the short stature could not be
determined. Five of  the children were also reported
to have idiopathic hypopituitarism. It was not possible
to define the cause of the hypopituitarism as we have
done in the case reported because of  lack of  facility.
Unlike this reported case, most of them presented
first in adolescence.6
Short stature is not a rare condition in childhood. Early
diagnosis is very essential for prompt institution of
therapy to enable short children to catch up and achieve
normal height.
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There are no known reported cases of combined
pituitary hormone deficiency in Nigerian children. This
is not because these cases are non-existent but due to
low level of awareness among health care providers
and lack of  facilities for diagnosis. This child with PIT-
1 mutation is evidence that this condition occurs in
African children.
PIT-1 mutations were first described in 1992 by four
independent groups7-10. Several mutations have been
described subsequently, with a total of  twenty- one
mutations described to date, and the most frequent







BMI HeightSDS WeightSDS BM ISDS
8.82 105.5 20 18.1 -4.57 -2.35 0.80
9.43 107 30.5 26.6 -4.66 0.04 2.83
9.73 117 34.5 25.2 -3.21 0.52 2.52
Table 3: Growth Parameters after starting rhGH
There was lack of facility in Nigeria for definitive
diagnosis in this patient. In addition, her parents have
to pay for growth hormone therapy. This is a very
huge burden for them. The use of GH was evidently
of immense value in this patient, not only to make her
grow taller, but it contributed to the improvement in
the psychosocial problems associated with short stature
in this child, enhancing adaptation to a better social
life in adulthood.
Furthermore, there were other logistic problems with
management and follow-up of this patient. GH was
F ig u r e  3
r h G H
not available in Nigeria and we had to procure it from
the United Kingdom. There were also problems with
storage of GH, which should be kept refrigerated.
There is incessant electricity power cut in the country
which can jeopardize the quality and efficacy of GH.
There is the need for the policy makers and the
government not only to be committed to provision
of appropriate equipment and facilities for the
diagnosis and management of childhood endocrine
disorders in the country but also the management of
non-communicable disorders in general. GH and other
hormones should be made available in the country so
that the cost of shipment can be eliminated.
Furthermore, health care providers in developing
countries should have a high index of suspicion when
patients present with short stature.
In conclusion, GH therapy has been beneficial for catch
up in height in this child. It also improved the
psychosocial problems associated with short stature
thereby enhancing adaptation to a better social life in
adulthood. For the Nigerian child; there are challenges
to achieving these goals. The health care providers and
the policy makers in Nigeria and other developing
countries have an important, significant and urgent role
to play in order to improve the outlook and quality
of  life for African children with endocrine disorders.
REFERENCES
1. Procter AM, Phillips IJA, and Cooper DN.  The
molecular genetics of  growth hormone deficiency.
Hum Genet 1998; 103:255–272.
2. Kelberman D., and Dattani MT. Hypopituitarism
oddities: congenital causes. Hormone Research.
2007; 68:138-144.
3. Rosenfeld MG., POU-domain transcription
factors: pou-er-ful developmental regulators.
Genes Dev. 1991; 5:897- 907.
4. Theil LE, and Karin M, Transcriptional control
of GH expression and anterior pituitary
development. Endocr Rev. 1993; 14:670-689.
5. Grote FK, Oostdijk W, De Muinck Keizer-
Schrama SM, Dekker FW, van Dommelen P, van
Buuren S, Lodder-van der Kooij AM, Verkerk
PH, and Wit JM. Referral patterns of children with
poor growth in primary health care. BMC Public
Health. 2007; 7: 77.
6. Famuyiwa OO. Short stature at the University
College Hospital, Ibadan, Nigeria. West Afr J Med.
1992;11:62-71.
7. Ohta K, Nobukuni Y, Mitsubuchi H, Fujimoto S,
Matsuo N, Inagaki H, Endo F, and Matsuda I.
Mutations in the PIT-1 gene in children with
combined pituitary hormone deficiency. Biochem
Biophys Res Commun 1992; 189:851–855.
8. Tatsumi K, Miyai K, Notomi T, Kaibe K, Amino
N, Mizuno Y, and KohnoH. Cretinism with
combined hormone deficiency caused by a
mutation in the PIT1 gene. Nat Genet 1992; 1:56–
58
9. Pfaffle RW, DiMattia GE, Parks JS, Brown MR,
Wit JM, Jansen M, Van der Nat H, Van den Brande
JL, Rosenfeld MG, and Ingraham HA. Mutation
of  the POU-specific domain of  PIT-1 and
hypopituitarism without pituitary hypoplasia.
Science 1992;  257:1118–1121
10. Radovick S,  Nations M, Du Y, Berg LA,
Weintraub BD, and Wondisford FE. A mutation
in the POU-homeodomain of  PIT-1 responsible
for combined pituitary hormone deficiency.
Science 1992; 257:1115–1118
11. Ward L, Chavez M, Huot C, Lecocq P, Collu R,
Decarie JC, Martial JA, and Van-Vliet G. Severe
congenital hypopituitarism with low prolactin
levels and age- dependent anterior pituitary
hypoplasia: a clue to a PIT-1 mutation. J Pediatr
1998; 132:1036–1038
12. Turton JP, Reynaud R, Mehta A, Torpiano J,
Saveanu A, Woods KS, Tiulpakov A, Zdravkovic
V, Hamilton J, Attard-Montalto S, Parascandalo
R, Vella C, Clayton PE, Shalet S, Barton J, Brue T,
and Dattani MT. Novel mutations within the
POU1F1 gene associated with variable combined
pituitary hormone deficiency. J Clin Endocrinol
Metab. 2005; 90: 4762-4770.
                                                   Annals of Ibadan Postgraduate  Medicine. Vol.6 No.2 December, 2008 26
